Valneva SE, , a specialty vaccine company, announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companie...
ProtoBind-Diff generates drug-like molecules for specific protein targets using only their amino acid sequences—no 3D structures required. The m...
Since 2019, Cytiva has committed over $1.6 billion to expand its global manufacturing capacity. In this exclusive conversation with BioPharma BoardRoom, Pi...
AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc....
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology ...
Enzene, a pioneer in fully-connected continuous biologics manufacturing technology, announced that ahead of the official opening of its biologics manufactu...
ADCs are no longer a niche modality. To date, there are over a dozen approved ADCs on the market, and more than 500 programs are in clinical development, d...
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
Taiwan's delegation, led by BPIPO (Biotechnology and Pharmaceutical Industries Promotion Office), organized by the Ministry of Economic Affairs, and...
Sinovac Biotech Ltd. (NASDAQ: SVA), a prominent player in China's biopharmaceutical sector, has entered a defining phase in its corporate history. As the...
Faster delivery and productivity gains available thanks to expanded manufacturing capacity in chromatography resins, filtration, single-use bag...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumo...
OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugate...
Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV)...
© 2025 Biopharma Boardroom. All Rights Reserved.
